IgG4-related orbital disease is the orbital manifestation of IgG4-related disease (IgG4-RD) and constitutes an important subgroup of orbital inflammatory diseases. IgG4-RD is a chronic, fibro-inflammatory systemic disease characterized by dense IgG4-positive plasma cell infiltration, storiform fibrosis, and obliterative phlebitis. In orbital involvement, lacrimal gland enlargement (bilateral dacryoadenitis) is most commonly seen; infraorbital nerve thickening (trigeminal V2 branch) is a characteristic finding that differentiates from other orbital inflammatory diseases. Orbital fat, extraocular muscles, and orbital nerves can also be involved. Bilateral and symmetric involvement is typical (60-80%). It is more common in middle-aged to older men. Simultaneous involvement of other organs such as pancreas (autoimmune pancreatitis), salivary glands (Mikulicz disease), retroperitoneum, and lymph nodes supports systemic disease.
Age Range
40-75
Peak Age
60
Gender
Male predominant
Prevalence
Rare
The pathophysiology of IgG4-related orbital disease begins with infiltration of IgG4-positive plasma cells and CD4+ T-lymphocytes into orbital tissues. Pro-fibrotic cytokines (IL-10, TGF-beta) and IgG4 antibodies produced by these immune cells trigger the tissue inflammation and fibrosis cascade. Storiform (star/wheel-shaped) fibrosis pattern forms from fibroblasts organizing in a characteristic spiral arrangement and is part of the diagnostic triad in histology. Obliterative phlebitis develops from occlusion of small veins by lymphoplasmacytic infiltration and fibrosis. Lacrimal gland predilection is explained by glandular tissue's rich immune cell content and lymphoid follicle structure. Infraorbital nerve (V2 branch) involvement leads to nerve thickening from perineural lymphoplasmacytic infiltration and fibrosis along the nerve sheath — the rarity of this pattern in other orbital inflammatory diseases increases its diagnostic value. Elevated serum IgG4 (60-70% of cases) reflects excessive IgG4 subclass antibody production, but normal serum IgG4 does not exclude the disease.
The most characteristic and distinguishing finding of IgG4-related orbital disease is perineural inflammatory infiltration and thickening along the infraorbital nerve (trigeminal V2 branch). While normal infraorbital nerve diameter is 1-2 mm, it can reach 3-5+ mm in IgG4-RD. Enhancement and thickening along the nerve on contrast-enhanced MRI are best demonstrated on coronal and sagittal reformats — the nerve is followed from the orbital floor to the pterygopalatine fossa. This finding is not typically seen in idiopathic orbital inflammation (pseudotumor), thyroid ophthalmopathy, and orbital lymphoma, carrying high diagnostic specificity for IgG4-RD. Bilateral infraorbital nerve thickening with bilateral lacrimal gland enlargement strongly supports the diagnosis.
On T2-weighted sequences, enlarged lacrimal glands show low to intermediate signal — resulting from dense lymphoplasmacytic infiltration and fibrosis component shortening T2 relaxation time. When fibrotic component is dominant, T2 signal is lower — appearing hypointense compared to normal lacrimal gland tissue. Infraorbital nerve thickening also shows similar low-intermediate T2 signal. If orbital fat and extraocular muscle involvement is present, intermediate signal is seen in these areas as well. Low T2 signal helps differentiate from other lacrimal gland pathologies (such as lacrimal gland lymphoma or pleomorphic adenoma).
Report Sentence
On T2-weighted sequences, bilateral lacrimal glands are enlarged and show low-intermediate signal — consistent with fibro-inflammatory process.
On contrast-enhanced MRI, enlarged lacrimal glands show homogeneous and intense enhancement — reflecting active inflammation and increased vascular permeability. Enhancement and thickening along the infraorbital nerve (V2) are observed — this nerve extends from the pterygopalatine fossa through the infraorbital canal to the orbital floor. If extraocular muscle involvement is present, muscles enhance. Diffuse enhancement accompanying orbital fat infiltration may be seen. Enhancement pattern differs from lacrimal gland lymphoma or pleomorphic adenoma — IgG4 shows more homogeneous enhancement that preserves gland shape.
Report Sentence
On contrast-enhanced series, homogeneous intense enhancement of bilateral lacrimal glands and enhancement with thickening along the infraorbital nerve are identified — findings consistent with IgG4-related orbital disease.
Contrast-enhanced CT demonstrates symmetric enlargement and homogeneous enhancement of bilateral lacrimal glands. While lacrimal glands are normally almond-shaped adjacent to the superolateral orbit, they show almond-beyond morphology with diffuse expansion in IgG4-RD. The infraorbital nerve (V2) is followed from the orbital floor and shows significant thickening compared to its normal diameter — best evaluated on coronal and sagittal reformats. Extraocular muscle thickening may accompany — generally less prominent than lacrimal gland. Erosion or destruction of orbital bones is not expected. Bilateral and symmetric involvement strongly suggests IgG4-RD.
Report Sentence
Contrast-enhanced CT demonstrates symmetric enlargement and homogeneous enhancement of bilateral lacrimal glands with thickening along the infraorbital nerve — consistent with IgG4-related orbital disease.
B-mode ultrasonography demonstrates enlargement and hypoechoic appearance of bilateral lacrimal glands. While normal lacrimal gland has homogeneous, medium echogenicity, in IgG4-RD involvement the gland is diffusely enlarged and echogenicity is decreased — reflecting inflammatory infiltration. Internal vascularity on Doppler may be increased. Lacrimal gland size (long and short axis) is measured and used for follow-up. Infraorbital nerve thickening can also be demonstrated on ultrasonography but evaluation is limited due to its deep location.
Report Sentence
Ultrasonography demonstrates diffuse enlargement and hypoechoic appearance of bilateral lacrimal glands.
FDG PET-CT demonstrates moderate-to-high FDG uptake (SUVmax 3-8) in bilateral lacrimal glands. In cases with systemic IgG4-RD involvement, involvement in other organs can also be demonstrated: pancreas, salivary glands, retroperitoneum, lymph nodes. PET-CT is valuable for systemic involvement mapping and treatment response assessment. PET-CT has limited value in differentiation from lacrimal gland lymphoma — both may be FDG avid; however, SUVmax is generally higher in lymphoma.
Report Sentence
FDG PET-CT demonstrates moderate FDG uptake (SUVmax: ...) in bilateral lacrimal glands, and evaluation for systemic IgG4-related disease involvement is recommended.
Criteria
Bilateral lacrimal gland enlargement is dominant finding. Extraocular muscle and orbital fat involvement minimal or absent. Most common IgG4 orbital involvement pattern.
Distinct Features
Differentiation from lacrimal gland lymphoma, sarcoidosis, and Sjögren syndrome is needed. Biopsy is critical for diagnosis — IgG4-positive plasma cells, storiform fibrosis, obliterative phlebitis is the diagnostic triad.
Criteria
Infraorbital nerve (V2) and/or supraorbital nerve (V1) thickening is dominant finding. Lacrimal gland involvement may or may not accompany. Facial numbness or pain may be a symptom.
Distinct Features
Differentiation from perineural tumor spread (adenoid cystic carcinoma, SCC) is critical. Enhancement and thickening pattern may be similar on MRI — clinical context and biopsy are decisive in differentiation.
Criteria
Simultaneous involvement of multiple orbital structures including lacrimal gland, extraocular muscles, orbital fat, and nerves. Shows diffuse orbital inflammation pattern.
Distinct Features
Differentiation from idiopathic orbital inflammation (pseudotumor) may be difficult — bilateral involvement and IgG4 serology help differentiation. Biopsy required for diagnosis.
Distinguishing Feature
Pseudotumor is generally unilateral (80-90%), painful, and acute-onset. Infraorbital nerve thickening is not typical. IgG4-RD is bilateral (60-80%), generally painless or mildly painful, with characteristic infraorbital nerve thickening. Serum IgG4 and biopsy provide definitive differentiation.
Distinguishing Feature
Orbital lymphoma shows marked restricted diffusion on DWI (low ADC), wraps structures with 'moulding' effect. Diffusion restriction is less prominent in IgG4-RD, and lower signal on T2 due to fibrosis. Infraorbital nerve thickening more specific for IgG4. Biopsy required for definitive diagnosis.
Distinguishing Feature
Thyroid ophthalmopathy shows bilateral muscle thickening (I'M SLow pattern), tendon sparing, and orbital fat increase. Lacrimal gland involvement secondary. In IgG4-RD, lacrimal gland is dominant, infraorbital nerve thickening is characteristic. Thyroid function tests and TRAb help differentiation.
Distinguishing Feature
Pleomorphic adenoma is a unilateral, well-circumscribed, slow-growing lacrimal gland mass. Shows bone remodeling in fossa lacrimalis. IgG4-RD is bilateral, preserves gland shape with diffuse enlargement, minimal bone remodeling. Pleomorphic adenoma is T2 hyperintense; IgG4 shows low-intermediate T2 signal.
Urgency
routineManagement
medicalBiopsy
NeededFollow-up
Serum IgG4 level for screening (>135 mg/dL suggestive). Biopsy with IgG4 immunohistochemistry for definitive diagnosis. Systemic staging (CT chest/abdomen/pelvis) for multi-organ involvement. Corticosteroids first-line (prednisone 0.6 mg/kg/day). Rituximab for steroid-refractory or relapsing disease.Management of IgG4-related orbital disease requires accurate diagnosis and systemic involvement assessment. Diagnosis is established by demonstrating the triad of IgG4-positive plasma cell infiltration (>10 IgG4+ cells/high-power field or IgG4/IgG ratio >40%), storiform fibrosis, and obliterative phlebitis on lacrimal gland biopsy. Elevated serum IgG4 is seen in 60-70% of cases but normal value does not exclude the diagnosis; elevated value alone is not diagnostic. Corticosteroids (prednisone 0.6 mg/kg/day) are first-line treatment with good response in >90% of cases — however, relapse rate is high (25-50%) with steroid tapering. Rituximab (anti-CD20) is effective second-line therapy for steroid-refractory or relapsing cases. Systemic staging (chest, abdominal CT; PET-CT) should be performed to demonstrate other organ involvement — pancreas (autoimmune pancreatitis), salivary glands, retroperitoneum, lymph nodes. Long-term follow-up is needed — relapse risk persists and multi-organ involvement may develop.
Responds to steroid therapy but recurrence is common. Rituximab is used in resistant cases. Systemic screening for other organ involvement is necessary (pancreas, retroperitoneum, salivary glands).